|
Guidance Optimizes Genotoxicity Tests, Aids in Risk Characterization
The FDA has revised its guidance on testing a new drug’s genotoxicity to help drugmakers optimize the standard genetic toxicology battery and better predict potential human risks.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Related Articles
FDA Recommends Separate Facilities for Non-Penicillin Beta-Lactam DrugsPhotostability Tests Alone Inadequate to Detect Phototoxic Starting Materials: GuidanceFDA Seeks Scientific Evidence for Limiting Opioid Prescriptions, UseFDA Recommends Early Systems Approach to Minimize Design-Related Medication Errors
|
Subscribe
Archives